Review

Digital Self-Management Support Tools in the Care Plan of Patients With Cancer: Review of Randomized Controlled Trials

Danielle JM Adriaans1,2, MSc; Angelique TM Dierick-van Daele2,3,4, PhD; Marc Johannes Hubertus Maria van Bakel4, MSc; Grard AP Nieuwenhuijzen1, MD, PhD; Joep AW Teijink1, MD, PhD; Fanny FBM Heesakkers1, MSc; Hanneke WM van Laarhoven5, MD, PhD

1Department of Surgery, Catharina Hospital, Eindhoven, Netherlands
2Fontys University of Applied Sciences, Eindhoven, Netherlands
3Department of Education and Research, Catharina Hospital, Eindhoven, Netherlands
4Fontys School of People and Health Studies, Eindhoven, Netherlands
5Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands

Corresponding Author:
Danielle JM Adriaans, MSc
Department of Surgery
Catharina Hospital
Michelangeloelaan 2
Eindhoven, 5602 ZA
Netherlands
Phone: 31 624720706
Email: danielle.adriaans@catharinaziekenhuis.nl

Abstract

Background: Digital self-management support tools (DSMSTs)—electronic devices or monitoring systems to monitor or improve health status—have become increasingly important in cancer care.

Objective: The aim of this review is to analyze published randomized clinical trials to assess the effectiveness of DSMSTs on physical and psychosocial symptoms or other supportive care needs in adult patients with cancer.

Methods: Five databases were searched from January 2013 to January 2020. English or Dutch language randomized controlled trials comparing DSMSTs with no intervention, usual care, alternative interventions, or a combination and including patients aged ≥18 years with pathologically proven cancer in the active treatment or survivorship phases were included. The results were summarized qualitatively.

Results: A total of 19 publications describing 3 types of DSMSTs were included. Although the content, duration, and frequency of interventions varied considerably across studies, the commonly used elements included an assessment component, tailored symptom self-management support, an information section, a communication section, and a diary. Significant positive effects were observed on quality of life in 6 (out of 10) studies, on anxiety in 1 (out of 5) study and depression in 2 (out of 8) studies, on symptom distress in 5 (out of 7) studies, on physical activity in 4 (out of 6) studies, on dietary behavior in 1 (out of 4) study, and on fatigue in 2 (out of 5) studies. Moreover, significant negative effects were observed on anxiety in 1 (out of 5) study and depression in 1 (out of 8) study. Most interventions were web-based interventions; 2 studies used mobile apps, and 1 study used a game as a DSMST. The overall quality of the studies was found to be good, with 13 out of 19 studies classified as high quality.

Conclusions: This review suggests that DSMSTs have a beneficial effect on the quality of life. For effects on other patient outcomes (eg, anxiety and depression, symptom distress, physical activity, dietary behavior, and fatigue), the evidence is inconsistent and limited or no effect is suggested. Future research should focus on specific tumor types, study different types of interventions separately, and assess the effects of specific interventions at different stages of disease progression.

(J Med Internet Res 2021;23(6):e20861) doi: 10.2196/20861
KEYWORDS
web-based intervention; digital self-management support tool; chronic patient groups; review; digital health; ehealth; mhealth; cancer patients; mobile phone

Introduction
Care for patients with cancer extends over a prolonged period, starting with the diagnostic phase, followed by a phase of active treatment and, subsequently, the follow-up phase (in the curative setting), or the supportive care phase (in the palliative setting). Considering the definition of chronic patients by the World Health Organization (patients who require “ongoing management for years or decades covering a wide range of health problems”), in some cases, patients with cancer may be considered as chronic patients [1].

Currently, people with a chronic condition are expected to play a more active role in their health care, which involves symptom management, adherence to treatment regimens, commitment to appropriate lifestyle changes, and the ability to deal with the psychological and physical consequences of their condition [2,3]. Studies related to chronic patients have demonstrated that self-management programs may be associated with reductions in anxiety and unscheduled physician visits and increases in self-efficacy [4-6].

Self-management of chronic disease is challenging for patients, and support from health care professionals is needed. Self-management support is defined as the systematic provision of education and supportive interventions by health care professionals to increase patients’ skills and confidence in managing their health problems, including regular assessment of progress and problems, goal setting, and problem-solving support [6]. Nowadays, it is offered through face-to-face contact and via digital tools.

Digital self-management support tools (DSMSTs) can be any type of electronic device (eg, website and app) or monitoring system (eg, smartwatch) that is applied by physicians in their health care practice or by individuals to monitor or improve their health status. Such tools can be used to stimulate a positive health behavior change, assist individuals to lead a healthier lifestyle, or support the diagnosis and treatment of diseases [7]. DSMSTs provide the means to facilitate communication between health care providers and patients, to transfer information, to improve some clinical outcomes (ie, physical outcome and functional status) among users, and to facilitate patient self-management, thus improving patient empowerment [6,8,9].

Although the population of patients with cancer is growing owing to the aging population and improved cancer care, complaints, needs, and preferences of patients with cancer can vary individually over different subjects and time [10], placing health care budgets under increasing strain. As a result, health authorities are seeking to lessen the burden by using technology to support a move toward self-care and outpatient long-term monitoring. With the rapid development of medical technology in health care, the use of DSMSTs to support patients with cancer will likely become increasingly important and could represent a helpful intervention to enhance psychological well-being (eg, increasing physical activity [PA]). Despite the projected proliferation of interventions with DSMSTs to manage treatment-related symptoms in patients with cancer, the evidence is lacking and the effectiveness of these tools is still unclear. Previously, researchers reviewed DSMSTs for patients with cancer and found promising results [11-15]. However, these reviews included studies that were primarily focused on cancer survivors [11-13,15] or focused only on a single outcome, that is, patient empowerment or fatigue [12,13,15], or a single digital medium, that is, mobile health [14]. The effects of DSMSTs from a broader perspective, including effects on physical and psychosocial symptoms or other supportive care needs, have not been reviewed before. Therefore, the overall objective of this review is to analyze published randomized clinical trials to assess the effectiveness of DSMSTs on physical and psychosocial symptoms or other supportive care needs in adult patients with cancer.

Methods

Eligibility Criteria for Article Selection

Study Design
Eligible studies were randomized controlled trials (RCTs) in English, performed in adult patients with cancer (≥18 years), published between January 2013 and January 2020, and comparing quantitative physical and/or psychosocial outcomes of DSMSTs with another intervention or usual care. Patients with cancer were defined as individuals diagnosed with any type of cancer, irrespective of disease stage, treatment phase, type of treatment, and time since diagnosis. When studies reported on mixed populations, only studies that reported data for patients with cancer separately were included.

Digital Self-Management Support Interventions
Digital self-management support was defined as self-management provided by DSMSTs. To be classified as a self-management support intervention, the intervention should meet criteria 1 and 2:

1. Self-management support targeted at physical or psychosocial symptoms or other supportive care needs of patients: Self-management support is defined as the systematic provision of education and supportive interventions by health care professionals to increase patients’ skills and confidence in managing their health problems, including regular assessment of progress and problems, goal setting, and problem-solving support.
2. A digital tool is used [5].

Programs that were not primarily designed to support or rehabilitate (eg, treatment decision aids and health behavior change interventions) were beyond the scope of this review and were excluded. Programs focusing exclusively on education were only included if the education aimed to support or rehabilitate patients with cancer (eg, group-based,
individual-based, structured, and unstructured). Cancer self-management education was defined as an ongoing process of facilitating the knowledge, skills, and confidence necessary to enable effective self-management of the biological, physical, and psychosocial effects of cancer and its treatment [16]. Studies describing interventions without access to the internet or a website were excluded.

**Outcomes**

Physical parameters related to activity level, dietary behavior, and fatigue and psychosocial parameters (e.g., anxiety and depression, quality of life [QOL], and symptom distress) were the outcomes of interest.

**Selection Method**

To identify potentially relevant studies, CINAHL, Embase, PsycINFO, Cochrane Network, and PubMed databases were searched for eligible RCTs from January 2013 to January 2020. The review began in 2018. Due to the rapid development of medical technology in health care, only studies from the last 5 years were included. During the time of writing this paper, the search was continually updated until January 2020, while maintaining the years 2013 and 2014, given the relevance of the included studies. The search strategy consisted of Medical Subject Headings combined with text words for cancer (Textbox 1) in a Boolean search. A medical information specialist checked the final search syntaxes. DJMA and MJHMVB screened the titles, abstracts, and full texts. Interresearcher reliability was checked using a 20% random sample of abstracts and full texts. Consensus was reached through discussion.

**Textbox 1.** Medical subject headings and keywords used.

| Medical Subject Headings |
|---------------------------|
| - self-management, self-management support, self-care, support, supportive care, health services needs and demand, patient education as topic, patient-centered care, health education, action plan, management plan, decision support techniques, continuity of patient care, patient decision making, computer assisted patient decision making, computer assisted decision support system, decision aid*, patient education, patient participation, physician-patient relations, patient information, medical information, decision support, decision tree, decision, decid*, consumer health information, interactive health communication, app, digital health, mobile technology, web based, computer, teledicine, eHealth, health technology, educational technology, mHealth, mobile phone, smartphone, mobile apps, internet, telecare |

| Keywords |
|---------|
| - cancer, neoplasm*, malignancy, malignancies, tumor |

**Data Extraction**

The following information was extracted from each publication: study characteristics (country of origin, year of publication, aim, and sample size), patient characteristics (age, gender, and type of disease), intervention characteristics (content, duration, and frequency), and outcome measures (instruments used and effects on physical and psychosocial outcomes). The first author independently extracted the data, and another author checked the data extraction for 20% of the studies to determine interrater reliability. Consensus was reached through discussion.

**Quality Assessment**

The methodological quality of the studies was evaluated, but it did not serve as an eligibility criterion. We used the CONSORT (Consolidated Standards of Reporting Trials) list developed by the CONSORT group to identify the problems arising from inadequate reporting of RCTs [17]. Items were scored using a tick mark. The tick marks indicate “yes” as an answer to the question, resulting in a maximum quality score of 37. For the qualitative synthesis, we counted the overall scores and classified them into 3 quality categories: high quality (CONSORT score >25), moderate quality (CONSORT score 13–25), and low quality. (CONSORT score <13)

Two reviewers (DJMA and MJHMVB) independently reviewed the papers and independently assessed the methodological quality. In case of disagreement, consensus was reached through discussion.

**Results**

**Selection of Publications**

Figure 1 outlines the search process. A total of 6047 references were identified through the search. Screening titles, abstracts, and full texts yielded 19 eligible studies.
Study Characteristics
A total of 19 publications were included (Figure 1); 3 publications were based on the same study, assessing different outcome measures [18-20]. The sample sizes ranged from 39 to 752 patients. All studies had a pre- and posttest design to measure the outcome differences in the groups. One study used 2 experimental groups [21], examining an internet-based patient-provider communication service with or without the additional use of a web-based illness management system, and another study used 2 experimental groups [22]: an unsupervised group that used a mobile app to record data or a supervised group that used the app and reviewed data with a physician. All other studies used a single experimental and control group (eg, control group assigned to a waiting list and received the intervention after the active treatment group, control group receiving written formats, and control group receiving usual care).

Quality of Included Studies
Table 1 presents the methodological quality of the studies. Allocation concealment was described in 9 studies [18-26]. Blinding of participants, personnel, and outcome assessors was adequately described in 8 studies [18,19,22,24,26-29]. Two studies explicitly described a nonblinded approach [21,30]. Out of 37 points, one study achieved 33 (89%) points and had the highest score [29]. A total of 13 studies were of high quality and 6 were of moderate quality [31].

Figure 1. Flowchart of included studies. RCT: randomized controlled trial.
Table 1. Quality of randomized controlled trials. To make them comparative, overall scores are counted (n, %; maximum score 33; n=37).

| Checklist item                                                                 | [34]\(^{f}\) | [33]\(^{f}\) | [32]\(^{f}\) | [31]\(^{f}\) | [30]\(^{f}\) | [29]\(^{f}\) | [28]\(^{f}\) | [27]\(^{f}\) | [26]\(^{f}\) | [25]\(^{f}\) | [24]\(^{f}\) | [23]\(^{f}\) | [22]\(^{f}\) | [21]\(^{f}\) | [20]\(^{f}\) | [19]\(^{f}\) | [18]\(^{f}\) | [17]\(^{f}\) | [16]\(^{f}\) | [15]\(^{f}\) | [14]\(^{f}\) | [13]\(^{f}\) | [12]\(^{f}\) | [11]\(^{f}\) | [10]\(^{f}\) | [9]\(^{f}\) | [8]\(^{f}\) | [7]\(^{f}\) | [6]\(^{f}\) | [5]\(^{f}\) | [4]\(^{f}\) | [3]\(^{f}\) | [2]\(^{f}\) | [1]\(^{f}\) |
|-----------------------------------------------------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| 1a. Identification as a randomized trial in the title                       | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| 1b. Structured summary of trial design, methods, results, and conclusions    | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              |
| 2a. Scientific background and explanation of rationale                      | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| 2b. Specific objective or hypotheses                                         | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| 3a. Description of trial design, including allocation ratio                  | X              | ✓              | ✓              | X              | ✓              | ✓              | X              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | X              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| 3b. Important changes to methods after trial commencement                   | ✓              | ✓              | ✓              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              |
| 4a. Eligibility criteria for participants                                     | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| 4b. Settings and locations where the data were collected                     | ✓              | X              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              |
| 5. Interventions for each group with sufficient details to allow replication | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| 6a. Completely defined prespecified primary and secondary outcome measures  | X              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| 6b. Any changes to trial outcomes after the trial commenced                 | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              |
| 7a. How sample size was determined                                           | ✓              | ✓              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              |
| 7b. Explanation of any interim analyses and stopping guidelines             | X              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| 8a. Method used to generate the random allocation sequence                   | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| 8b. Type of randomization                                                    | ✓              | ✓              | X              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| 9. Mechanism used to implement the random allocation sequence               | ✓              | X              | X              | ✓              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              |
| 10. Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | X              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              |
| 11a. Who was blinded after assignment and how                               | ✓              | X              | 🌡️             | X              | X              | X              | X              | X              | X              | X              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| 11b. Description of similarity of interventions                              | ✓              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              | X              |
| 12a. Statistical methods used to compare groups for primary and secondary outcomes | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| 12b. Methods for additional analyses                                        | X              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| 13a. For each group, the numbers of participants who were randomly assigned, who received intended treatment, and who were analyzed for the primary outcome | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| Checklist item                                                                 | [34] | [30] | [21] | [20] | [32] | [25] | [27] | [29] | [33] | [30] | [18] | [19] | [22] | [34] | [35] | [36] | [37] | [28] |
|--------------------------------------------------------------------------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| 13b. For each group, losses and exclusions after randomization, together with reasons | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | X    |
| 14a. Dates defining the periods of recruitment and follow-up                     | X    | ✓    | ✓    | ✓    | X    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | X    |
| 14b. Why the trial ended or was stopped                                          | X    | X    | ✓    | X    | X    | ✓    | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    |
| 15. A table showing baseline demographic and clinical characteristics for each group | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | X    |
| 16. For each group, number of participants included in each analysis and whether the analysis was by original assigned groups | ✓    | ✓    | ✓    | X    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | X    | ✓    | ✓    | ✓    | ✓    | ✓    | X    |
| 17a. For each primary and secondary outcome, results for each group and the estimated effect size and its precision were noted | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    |
| 17b. For binary outcomes, presentation of both absolute and relative effect sizes is recommended | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    | X    |
| 18. Results of any other analyses performed                                        | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | X    | X    | ✓    |
| 19. All important harms or unintended effects in each group                         | X    | X    | ✓    | X    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | X    | ✓    | ✓    | ✓    | ✓    | ✓    |
| 20. Trial limitations                                                              | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | X    | ✓    | ✓    | ✓    | ✓    | ✓    |
| 21. Generalizability of the trial findings                                          | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    |
| 22. Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    |
| 23. Registration number and name of trial registry                                  | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | X    | X    | ✓    | ✓    | ✓    | ✓    |
| 24. Where the full trial protocol can be accessed                                    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | ✓    | X    |

https://www.jmir.org/2021/6/e20861
Description of Participants

The 19 studies included 5186 patients. Eleven studies included patients in the active treatment phase [21-25,27,28,33-36]. Eight studies included patients who had finished active treatment and were in the curative setting, in the follow-up phase, or in the palliative setting, in the supportive care phase [18-20,26,29,30,32,37]. Nine studies were related to DSMSTs for patients with breast cancer [21,22,24-27,29,32,34]. Six studies were related to patients with cancer in general [18-20,23,33,37]. Two studies included 129 newly diagnosed patients with cancer, of whom 92 were treated for breast cancer [35], and 625 cancer survivors, of which 138 were treated for breast cancer [30]. Two breast cancer studies focused on patients undergoing chemotherapy [22,24]. Of the remaining studies, 1 study focused on 261 patients with primary cancers that had metastasized to the liver and 1 study on 285 patients with nonsmall cell lung cancer [28,36]. The mean number of participants was 273 (range 39-752), of which 70.99% (3682/5186) were female. Some studies included only female participants. The mean age of the subjects was 54.2 years (range 42.35-61.7; Table 2).
Table 2. Characteristics of included studies: population, intervention and comparison descriptions, and study design (N=19).

| Reference and country       | Population                                    | Stage of care process | Intervention                                      | Technological components                                                                 | Comparison                  | Length of intervention | Follow-up                      |
|-----------------------------|-----------------------------------------------|-----------------------|--------------------------------------------------|-------------------------------------------------------------------------------------------|----------------------------|------------------------|--------------------------------|
| Børøsund et al [21], Norway | 167 patients recently diagnosed with breast cancer | Active cancer treatment | Web-based self-management support system and e-messages | Assessment component to monitor and report symptoms, problems, and priorities for support along physical, functional, and psychosocial dimensions; tailored symptom self-management support; information section; communication section; and diary | Care as usual               | Minimally 6 months        | Baseline, 2 months, 4 months, and 6 months |
|                            |                                               |                       |                                                  |                                                                                           |                            |                       |                                |
| Ruland et al [25], Norway   | 325 patients with breast cancer (surgery plus additional treatment) or prostate cancer | Active cancer treatment | Web-based self-management support system | Assessment component to monitor and report symptoms, problems, and priorities for support along physical, functional, and psychosocial dimensions; tailored symptom self-management support; information section; communication section; and diary | Information sheet with relevant internet sites that could be useful to them | 1 year                  | Baseline, 3 months, 6 months, 9 months, and 2 months |
| Ryhänen et al [27], Finland | 300 newly diagnosed patients with breast cancer | Active cancer treatment | Web-based patient education tool | Information section | Usual care: oral and written patient education material | Average 9 months | Just before surgery, 1 day after surgery, when meeting the oncologist for the first time, before and after chemotherapy, before and after radiotherapy, and 1 year after breast cancer diagnosis |
| Beatty et al [23], Australia | 60 patients with cancer                        | Active cancer treatment | Self-guided, web-based cognitive behavioral therapy | Tailored symptom self-management support | Information-only version of CCO, contained the same 6 information topics as the intervention but no worksheets, activities, relaxation or meditation exercises, or journal | 6 weeks                  | Baseline, immediately postintervention, 3 months postintervention, and 6 months postintervention |
| Berry et al [33], United States | 752 ambulatory adult participants with various cancer diagnoses | Active cancer treatment | Web-based, self-report assessment and educational intervention | Assessment component to monitor and report symptoms, problems, and priorities for support along physical, functional, and psychosocial dimensions; information section; communication section; and diary | Screening for symptom or QOL | From the start of a new therapeutic regimen till 2-4 weeks after treatment ended | Before a new therapeutic regimen, 3-6 weeks after starting treatment, 2 weeks later, and 2-4 weeks after treatment ended |
| Reference and country | Population | Stage of care process | Intervention | Technological components | Comparison | Length of intervention | Follow-up |
|-----------------------|------------|-----------------------|--------------|--------------------------|------------|------------------------|-----------|
| Urech et al [35], Switzerland | 129 newly diagnosed patients with cancer (92 treated for breast cancer) | Active cancer treatment | Web-based intervention on stress management | Tailored symptom self-management support<sup>b</sup> | Wait-list control | At least 8 weeks | Baseline, postintervention, and 2-month follow-up |
| Steel et al [28], United States | 261 patients diagnosed with hepatocellular, cholangiocarcinoma, gallbladder, neuroendocrine, and pancreatic carcinoma or other primary cancers that have metastasized to the liver | Active cancer treatment | Web-based self-management support system | Assessment component to monitor and report symptoms, problems, and priorities for support along physical, functional, and psychosocial dimensions<sup>a</sup>; tailored symptom self-management support<sup>b</sup>; information section<sup>c</sup>; communication section<sup>d</sup>; and diary<sup>e</sup> | Usual care | 6 months | Baseline and 6 months |
| Gustafson et al [36], United States | 285 dyads consisting NSCLC<sup>b</sup> at stage IIIA, IIIB, or IV—patients and a patient-identified primary caregiver | Active cancer treatment | Web-based intervention | Information section<sup>c</sup> and communication section<sup>d</sup> | Training on using the internet and a list of internet sites about lung cancer | 25 months or 13 months after patient death, whichever was less | Baseline, 2 months, 4 months, 6 months, and 8 months after the intervention |
| Egbring et al [22], Switzerland | 139 patients with breast cancer undergoing chemotherapy | Active cancer treatment | Mobile app, supervised, and unsupervised | Assessment component to monitor and report symptoms, problems, and priorities for support along physical, functional, and psychosocial dimensions<sup>a</sup> | Usual care | 6 weeks | Day 1, day 21, and day 42 during their chemo-therapeutic intervention |
| Foley et al [34], Ireland | 39 patients with breast cancer undergoing surgery | Active cancer treatment | Mobile app | Information section<sup>c</sup> | Not specified | 2 weeks | At enrolment, 1 day before surgery, 1 day postsurgery, and 7 days postsurgery |
| Kim et al [24], Republic of Korea | 76 patients with metastatic breast cancer planned to receive chemotherapy | Active cancer treatment | Mobile game | Information section<sup>c</sup> | Usual care+<sup>a</sup> brochure with side effects of chemotherapy | 3 weeks | Baseline and after 3 weeks |
| Galiano-Castillo et al [26], Spain | 81 patients with breast cancer after completing adjuvant therapy | Finished active cancer treatment | Web-based tailored exercise program | Tailored symptom self-management support<sup>b</sup> and communication section<sup>d</sup> | Basic recommendations (written format) for exercise | 8 weeks | Baseline, 8 weeks, and 6 months |
| van den Berg et al [29], the Netherlands | 150 female breast cancer survivors 2-4 months before baseline assessment | Finished active cancer treatment | Web-based self-management support system | Assessment component to monitor and report symptoms, problems, and priorities for support along physical, functional, and psychosocial dimensions<sup>e</sup>; tailored symptom self-management support<sup>b</sup>; and information section<sup>c</sup> | Care as usual | 4 months | Baseline, 4 months, 6 months, and 10 months |
| Reference and country | Population | Stage of care process | Intervention | Technological components | Comparison | Length of intervention | Follow-up |
|-----------------------|------------|-----------------------|--------------|--------------------------|------------|-----------------------|-----------|
| Lee et al [32], South Korea | 59 patients with breast cancer who had received curative surgery and completed primary cancer treatment within 12 months before the study: diagnose stage 0-III cancers within 2 years before the study | Finished active cancer treatment | Web-based self-management exercise and diet intervention support system | Assessment component to monitor and report symptoms, problems, and priorities for support along physical, functional, and psychosocial dimensions, tailored symptom self-management support, information section; communication section; and diary | Intervention: a 50-page educational booklet on exercise and diet | 12 weeks | Baseline and 12 weeks |
| Van der Hout et al [30], the Netherlands | 625 survivors diagnosed with head and neck cancer, colorectal cancer, breast cancer, Hodgkin lymphoma, or non-Hodgkin lymphoma | Finished active cancer treatment | Web-based eHealth app | Assessment component to monitor and report symptoms, problems, and priorities for support along physical, functional, and psychosocial dimensions, tailored symptom self-management support, information section; and communication sectiond | Wait-list control group (access to app after 6 months) | 6 months | Baseline, 1 week postintervention, 3 months, and 6 months |
| Willems et al [20], the Netherlands | 462 patients with cancer from 21 different Dutch hospitals | Finished active cancer treatment | Web-based self-management support system | Tailored symptom self-management support, and information section | Access to the intervention was postponed until after the 12-month measurement | 12 months | Baseline, 3 months, 6 months, and 12 months |
| Kanera et al [18], the Netherlands | Same intervention as that used by Willems et al [20] | Finished active cancer treatment | Web-based self-management support system | Tailored symptom self-management support, and information section | Access to the intervention was postponed until after the 12-month measurement | 6 months | Baseline, 3 months, 6 months |
| Kanera et al [19], the Netherlands | Same intervention as that used by Willems et al [20] | Finished active cancer treatment | Web-based self-management support system | Tailored symptom self-management support, and information section | Access to the intervention was postponed until after the 12-month measurement | 12 months | Baseline, 3 months, 6 months, and 12 months |
Børøsund et al [21], patients could choose symptoms and problems the patient experiences (eg, in the study by symptom self-management support to self-manage symptoms and stress management via relaxation therapy); (2) Tailored symptom self-management support along physical, functional, and psychosocial dimensions; (3) information section; (4) communication section; and diary. Although the content of the interventions differed, 5 key components of DSMSTs [21,25,28,29,32,37] to increase self-management (support): (1) An assessment component to monitor and report symptoms, problems, and priorities for support along physical, functional, and psychosocial dimensions; (2) Tailored symptom self-management support to self-manage symptoms and problems the patient experiences; (3) The information section, which included information about various aspects of cancer such as exercise, nutrition, coping, and symptom management and also provided access to other reliable and relevant web sources; (4) Communication section, with fellow patients or with health care providers, using discussion centers, an SMS text messaging function, or email as a communication tool. Communication with fellow patients was often used for social networking, providing feedback, and encouraging each other, whereas communication with health care providers was often used for difficult questions and support; (5) Diary, where patients could keep personal notes. One offered tailored information and the other offered an assessment component only offered 1 of the 5 key components. One offered tailored symptom self-management support; (6) Diary, where patients could keep personal notes. The 2 studies that provided a mobile app only offered 1 of the 5 key components. One offered tailored information and the other offered an assessment component (Table 2) [22,34]. One study, using a mobile game, offered patient education as a key component to increase the self-management of patients with breast cancer [24].

### Intervention Characteristics

The intervention characteristics for both the intervention and control groups are described in Table 2. The degree of detail provided about the interventions varied greatly across studies. There was a large variation in the duration, frequency, and content of the interventions. The mean duration of the intervention was 39.5 weeks (range 2 weeks to 25 months). A total of 37% (7/19) interventions focused only on the psychological well-being of patients [27,29,30,33-36], 1 focused only on physical health [32], and 11 focused on both [18-26,28,37].

The technological component was mainly a web-based approach (16/19, 84%) [18-21,23,25-30,32,33,35-37]; in 2 studies, a mobile app was used [22,34], and 1 study used a mobile game as a DSMST [24]. Of the 16 studies that used a web-based approach, 1 study sent email reminders in an attempt to maintain or improve adherence [29].

Although the content of the interventions differed, 5 key components of DSMSTs were identified (Table 2). A total of 5 of the 16 web-based approach studies used all 5 key components in their DSMSTs [21,25,28,29,32,37] to increase self-management (support): (1) An assessment component to monitor and report symptoms, problems, and priorities for support along physical, functional, and psychosocial dimensions, currently and over time (eg, improving diet, increasing exercise, and stress management via relaxation therapy); (2) Tailored symptom self-management support to self-manage symptoms and problems the patient experiences (eg, in the study by Børøsund et al [21], patients could choose symptoms and problems they were experiencing from a predefined list, rate the burden of these symptoms and problems, and indicate where they needed help); (3) The information section, which included information about various aspects of cancer such as exercise, nutrition, coping, and symptom management and also provided access to other reliable and relevant web sources; (4) Communication section, with fellow patients or with health care providers, using discussion centers, an SMS text messaging function, or email as a communication tool. Communication with fellow patients was often used for social networking, providing feedback, and encouraging each other, whereas communication with health care providers was often used for difficult questions and support; (5) Diary, where patients could keep personal notes. The 2 studies that provided a mobile app only offered 1 of the 5 key components. One offered tailored information and the other offered an assessment component (Table 2) [22,34]. One study, using a mobile game, offered patient education as a key component to increase the self-management of patients with breast cancer [24].

### Outcomes of Included Studies

The measurement instruments used and the corresponding outcomes of the studies are presented in Table 3. Psychosocial outcome measures, such as QOL, anxiety and depression, and symptom distress, were the most commonly used outcome measures, mostly using validated (eg, The European Organisation for Research and Treatment of Cancer QOL Questionnaire Core 30, Functional Assessment of Cancer Therapy-Fatigue, Hospital Anxiety and Depression Scale [HADS]) questionnaires.
Table 3. Intervention outcomes.

| Reference and country          | Outcomes and measurement instruments | Results                                                                 |
|-------------------------------|---------------------------------------|--------------------------------------------------------------------------|
| Børøsund et al [21], Norway   | Anxiety, depression, (HADS\(^c\)), and symptom distress (MSAS\(^d\)) | • Anxiety: intervention+communication service<control (<i>P</i>=.03)      |
|                               |                                       | • Intervention+communication service versus communication service: NS    |
|                               |                                       | • Depression: intervention+communication service<control (<i>P</i>=.03)  |
|                               |                                       | • Depression: communication service<control (<i>P</i>=.03)              |
|                               | QOL\(^a\)                             | • Intervention+communication service<control (<i>P</i>=.01)             |
|                               | Distress (symptom)                    | • Intervention+communication service versus communication service: NS  |
|                               | Fatigue                               | • Intervention+communication service versus communication service: NS  |
|                               | PA\(^b\)                              | • intervention+communication service versus communication service: NS  |
|                               | Dietary behavior                      | • intervention+communication service versus communication service: NS  |

Ruland et al [25], Norway
Symptom distress (MSAS), depression (Center for Epidemiological Studies-Depression Scale), self-efficacy, and social support

- Intervention<control (<i>P</i>=.18)
- Depression: intervention<control (<i>P</i>=.16)

- Intervention<control (<i>P</i>=.04; only on global symptom distress index)

Ryhänen et al [27], Finland
QOL (QOL-CS\(^f\)), anxiety (STAI\(^h\)), and side effects

- Intervention=control (<i>P</i>=.82)
- Anxiety: intervention=control (<i>P</i>=.64)

- —
- —
- —
- —
| Reference and country       | Outcomes and measurement instruments                                                                 | Results                                                                 |
|----------------------------|--------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Beatty et al [23], Australia | Distress (PSS-SR\(^1\), DASS\(^2\), HRQOL\(^3\) (EORTC-QLQ-C30\(^3\)), and coping (mini-MAC\(^m\)) | • Interventions > control at 3-month follow-up                          |
|                            |                                                                                                       | • Interventions = control at 3-month follow-up                           |
|                            |                                                                                                       | • Interventions > control at 6-month follow-up for global QOL (\(d=0.43\)) |
|                            |                                                                                                       | Trend toward a significant group × time interaction for global QOL     |
|                            |                                                                                                       | —                                                                       |
| Berry et al [33], United States | Symptom distress (SDS-15\(^n\) score)                                                               | • The SDS-15 score was reduced by an estimated 1.53 points (\(P=.01\)) in the intervention group compared with the matched control group. |
|                            |                                                                                                       | —                                                                       |
| Urech et al [35], Switzerland | QOL (FACT-F\(^o\)), anxiety or depression (HADS), and distress (distress thermometer)                | • Interventions > control (\(P=.07\))                                 |
|                            |                                                                                                       | • Interventions = control (\(P=.15\))                                 |
|                            |                                                                                                       | • Interventions < control (\(P=.03\))                                 |
|                            |                                                                                                       | • Immediately after the intervention                                   |
|                            |                                                                                                       | • After 2 months, intervention = control                                |
| Steel et al [28], United States |                                                                                                       | • Interventions: QOL increased (Cohen \(d=0.99\))                       |
|                            |                                                                                                       | • Interventions: depression decreased (Cohen \(d=0.71\))               |
|                            |                                                                                                       | • Interventions: NS                                                    |

\(^{a}\) QOL

\(^{b}\) PA
| Reference and country | Outcomes and measurement instruments | Results |
|-----------------------|--------------------------------------|---------|
|                       | QOL<sup>a</sup> Anxiety and depression Distress (symptom) Fatigue PA<sup>b</sup> Dietary behavior |
| Gustafson et al [36], United States | Symptom distress (ESAS<sup>t</sup>) | — | — | • Intervention<control | — | — | — |
|                       | Depression (Center for Epidemiological Studies-Depression), pain (BPI<sup>p</sup>), fatigue (FACT<sup>q</sup> instrument), HRQOL (FACT-G<sup>r</sup>), and caregiver stress and depression (CQOLC<sup>s</sup> and Center for Epidemiological Studies-Depression scale) | — | | | | | |
| Egbring et al [22], Switzerland | Daily functional activity (ECOG<sup>u</sup>) | — | — | — | — | — |
| Reference and country | Outcomes and measurement instruments | Results                                                                 |
|-----------------------|-------------------------------------|------------------------------------------------------------------------|
| Foley et al [34],     | Anxiety and depression (HADS)       | • Decreased; All groups from first to second visit                     |
| Ireland               |                                     | • Increased; Intervention: supervised from second to third visit       |
|                       |                                     | • Decreased; Intervention: unsupervised and control                    |
|                       |                                     | • Intervention: supervised from first (median 90.85, IQR 30.67) to third visit (median 84.76, IQR 18.29; P=.72) |
| Kim et al [24],       | QOL (WHO QOL-BREF<sup>v</sup> Scale), anxiety (Spielberger State-Trait anxiety scale), and depression (BDI<sup>w</sup>) | • Control<sup>a</sup>-intervention 7 days postoperative (P=.03, anxiety; P=.02; depression) |
| Republic of Korea     |                                     | • Intervention<sup>b</sup>-control (P=.01)                             |
|                       |                                     | • Anxiety: intervention<sup>b</sup>-control (P=.21)                     |
|                       |                                     | • Depression: intervention<sup>b</sup>-control (P=.99)                  |
| Galiano-Castillo et al [26], Spain | QOL (EORTC-QLQ-C30) and fatigue (R-PFS<sup>x</sup>) | • Fatigue                                                                |
|                       |                                     | • Intervention<sup>b</sup>-control (P<.001)                             |

<sup>a</sup> QOL: Quality of Life;<sup>b</sup> PA: Physical Activity;<sup>x</sup> R-PFS: Real-time Pain Fatigue Scale;<sup>y</sup> WHO QOL-BREF: World Health Organization Quality of Life Brief Scale;<sup>v</sup> Spielberger State-Trait anxiety scale;<sup>w</sup> BDI: Beck Depression Inventory.
| Reference and country | Outcomes and measurement instruments | Results | Anxiety and depression | Distress (symptom) | Fatigue | PA<sup>b</sup> | Dietary behavior |
|-----------------------|--------------------------------------|---------|------------------------|--------------------|---------|------------|------------------|
| **Intervention vs control for global health status (<i>P</i>=.001), physical functioning (<i>P</i>=.001), role functioning (<i>P</i>=.003), and cognitive functioning (<i>P</i>=.007), and arm symptoms (<i>P</i>=.003),** | | | | | | | |
| Berg et al [29], the Netherlands | Distress (SCL-90<sup>a</sup>) | — | — | — | — | Intervention vs control (<i>P</i>=.02) | |
| Lee et al [32], South Korea | HRQOL (EORTC-QLQ-C30), exercise and intake of Fruit and vegetables, diet quality (DQI<sup>b</sup>), stage of change for exercise, and fatigue (BFI<sup>ab</sup>) | • Intervention vs control (<i>P</i>=.02) | — | — | — | Intervention vs control (<i>P</i>=.03) | Moderate-intensity aerobic exercise: intervention vs control (<i>P</i>&lt;.001) |
| | | | | | | • Physical functioning: intervention vs control (<i>P</i>=.02) | Appetite loss: intervention vs control (<i>P</i>=.03) |
| | | | | | | • Stage of change for exercise: intervention vs control (<i>P</i>&lt;.001) | Fruit and vegetables consumption: intervention vs control (<i>P</i>=.03) |
| Van der Hout et al [30], the Netherlands | HRQOL (EORTC-QLQ including tumor-specific symptoms within the tumor groups) | • Intervention vs control over time (<i>P</i>=.05) | — | — | — | — | |
| Willems et al [20], the Netherlands | Emotional and social functioning (EORTC-QLQ-C30), depression (HADS), and fatigue (CIS<sup>ab</sup>) | • Emotional and social functioning | — | — | — | — | |
| | | • 6 months: intervention ↓ for participants who received chemotherapy (<i>d</i>=0.36) | 6 months: intervention — | — | — | — | |
| | | • 12 months: intervention = control | 12 months: intervention = control | 12 months: intervention = control | — | — | |

---

**Note:**
- QOL<sup>a</sup> = Quality of Life
- PA<sup>b</sup> = Physical Activity

---

https://www.jmir.org/2021/6/e20861
| Reference and country | Outcomes and measurement instruments | Results | Dietary behavior |
|-----------------------|--------------------------------------|---------|------------------|
| Kanera et al [18], the Netherlands | PA (SQUASH<sup>c</sup>) and dietary behavior (Dutch Standard Questionnaire on Food Consumption) | • Moderate PA intervention>control (<sup>b</sup>P<.001) | • Intervention>control (<sup>b</sup>P=.02) |
| Kanera et al [19], the Netherlands | Moderate PA (SQUASH) and vegetable consumption (Dutch Standard Questionnaire on Food Consumption) | • After multiple testing, significance expired | • Vegetable consumption: intervention>control (<sup>b</sup>P=.12) |
| Bantum et al [37], United States | Fatigue (BFI), exercise (Godin Exercise Questionnaire), fruit and vegetable intake (Block Food Frequency Questionnaire), and depression (PHQ<sup>d</sup>ad-8) | • Depression: intervention=control (<sup>b</sup>P=.69) | • Intervention>control (<sup>b</sup>P=.01), increase of strenuous exercise (32-51 min per week compared with a steady 29 min per week) |

<sup>a</sup>QOL: quality of life.
<sup>b</sup>PA: physical activity.
<sup>c</sup>HADS: Hospital Anxiety and Depression Scale.
<sup>d</sup>MSAS: Memorial Symptom Assessment Scale.
<sup>e</sup>Not available.
<sup>f</sup>NS: nonsignificant.
<sup>g</sup>QOL-CS: Quality of Life Cancer Survivor.
<sup>h</sup>STAI: State-Trait Anxiety Inventory.
<sup>i</sup>PSS-SR: Posttraumatic Stress Scale-Self-Report.
<sup>j</sup>DASS: Depression Anxiety Stress Scale.
A total of 10 studies reported QOL [20,23-28,30,32,35], whereas 6 of them reported positive outcomes [24,26,28,30,32,35]. A few studies (4/9, 44%) used the European Organisation for Research and Treatment of Cancer Questionnaire Core 30 to measure QOL. Four studies observed that the overall health-related QOL improved to a significantly larger degree compared with the control group [24,28,30,35]. Two of these studies [24,30] were of high quality, including 76 and 625 participants, respectively. One study, including 81 patients who finished active treatment, with 8 weeks of access to an internet-based tailored exercise program, found that health-related QOL improved to a significantly larger degree compared with the control group on the subdomains global health status, physical functioning, role functioning, cognitive functioning, and arm symptoms [26]. One study, which reported on 59 patients with breast cancer who finished active treatment, only found a statistically significant difference in the subdomain physical functioning [32]. Four studies [20,23,25,27] found no statistically significant differences in the overall QOL or subdomains of QOL. Three of these studies included >300 patients each, of which 2 studies were of high quality.

Anxiety was reported in 5 studies, whereas depression was reported in 8 studies. Four studies [21,24,34,35] reported anxiety and depression. Four studies used the HADS [20,21,34,35] to report anxiety and depression. Willems et al [20] used only the depression subscales of the HADS. Two other studies also reported depression using different questionnaires [28,37]. One study only reported the outcomes of anxiety [27]. Two studies reported significant differences in anxiety levels [21,34], and 3 studies reported significant differences in depression levels [21,28,34]. One of these studies, including 167 patients with breast cancer in active treatment with access to a web-based self-management support system with e-messages, observed significantly lower anxiety (P=0.03) and depression (P=0.03) levels in the intervention group than in the usual care group [21]. This study was classified as high quality. Another study, classified as moderate quality and including 261 active treatment patients, reported a reduction in depression (Cohen d=0.71) for the intervention group when compared with the usual care group [28]. In contrast, another moderate quality study including 39 patients with breast cancer with access to a mobile app for 2 weeks, reported significantly lower anxiety (P=0.02) and depression (P=0.03) levels in the control group than in the intervention group [34]. Of the studies that found no significant differences in anxiety, 2 studies were of moderate quality, whereas 1 was classified as high quality, including 76 patients who completed active cancer treatment. Of the studies that found no significant differences in depression, 2 studies were of moderate quality, whereas 3 [20,24,25] were classified as high quality. One of these studies included 76 patients who completed active cancer treatment and 2 of these studies included 325 patients, during their active cancer treatment.

A total of 7 studies reported symptom distress [21,23,25,29,33,35,36], of which 6 were classified as high-quality studies. One study [35] was classified as moderate quality. All studies used a web-based approach. One study (including 167 active treatment patients), using 2 experimental groups [26] and examining an internet-based patient-provider communication service with and without the additional use of a web-based illness management system, found significantly lower symptom distress in the web-choice intervention group than in the control group, but no statistically significant differences were observed between the 2 intervention groups [21]. In addition, 2 other studies, including 150 and 752 patients, found significantly less distress in the intervention group [29,33]. Another study, including 325 patients, found significant group differences in symptom distress [25]. One study included 285 active treatment patients and their primary caregivers [36]. These caregivers reported lower patient physical symptom distress in the intervention group than in the control group. One study found that distress was significantly lower immediately after the intervention in the intervention group than in the control group.

kHRQOL: health-related quality of life.
1EORTC-QLQ-C30: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30.
imini-MAC: mini Mental Adjustment to Cancer Scale.
SDS-15: 15-item Symptom Distress Scale.
FACT-F: Functional Assessment of Cancer Therapy-Fatigue.
BFI: Brief Pain Inventory.
FACT: Functional Assessment of Cancer Therapy.
FACT-G: Functional Assessment of Cancer Therapy-General.
CQOLC: Caregiver Quality of Life Index-Cancer Scale.
ESAS: Edmonton Symptom Assessment Scale.
ECOG: Everyday Cognition.
WHO QOL BREF scale: World Health Organization Quality of Life-BREF Scale.
BDI: Beck Depression Inventory.
P-: Piper Fatigue Scale-Revised.
SCL-90: Symptom Checklist-90.
DQI: Diet Quality Index.
BFI: Brief Fatigue Inventory.
CIS: Checklist Individual Strength.
SQUASH: Short Questionnaire to Assess Health-Enhancing Physical Activity.
PHQ: Patient Health Questionnaire.

https://www.jmir.org/2021/6/e20861
J Med Internet Res 2021 | vol. 23 | iss. 6 | e20861 | p. 18
(page number not for citation purposes)
group. However, distress did not change significantly from immediately after the intervention to the follow-up 2 months later [35]. One study, including 60 patients, found no statistically significant group x time interactions [23].

Five studies reported fatigue [20,26,28,32,37], of which 2 reported a decrease in fatigue after 8 and 12 weeks of a web-based intervention [26,32]. One of these studies, including 81 patients, was classified as high quality. Three others found no significant changes after an intervention of 6 months [20,28,37], of which 1 was classified as high quality, including 462 patients.

Six studies reported results on PA [18,19,22,23,32,37]. Four studies observed significant effects; 2 studies were classified as high quality [19,23], whereas 2 were classified as moderate quality [32,37]. In 1 study, 139 participants were randomly assigned to an unsupervised group (intervention), a supervised group (intervention), or a control group [22]. The intervention groups showed no significant differences from the first to the third visit. On the other hand, another study including 352 patients who finished active treatment with 6 months of access to a web-based self-management support system, showed an increase in strenuous exercise in the intervention group compared with the control group [37]. Another study found that moderate-intensity aerobic exercise for at least 150 minutes per week significantly increased in the intervention group compared with controls [32]. In the study by Beatty et al [23], 60 participants received either the 6-week intervention Cancer Coping Online (n=30) or the 6-week web-based attention control (n=30). The Cancer Coping Online participants had significantly higher physical functioning than the controls at 3 months of follow-up (d=−0.52; P=.02). The study that found no significant effect [18] was similar to a study that found a significant effect, with the only difference in follow-up time (6 months vs 12 months) [19].

Four studies reported dietary behaviors [18,19,32,37]. One study, including 59 patients with 12 weeks of access to a web-based self-management exercise and diet intervention support system, showed a greater improvement in overall diet quality in the intervention group (P=.001) [32]. Another study, including 352 patients who finished active treatment with 6 months of access to a web-based self-management support system, reported no significant changes in fruit and vegetable intake [37]. Both studies were classified as moderate quality. Two high-quality studies of 462 patients, who completed active treatment, found no significant changes in dietary behavior and vegetable intake in particular [18,19].

Discussion

Principal Findings

In this paper, we have systematically reviewed published RCTs to assess the effectiveness of existing interventions with DSMSTs on physical and psychosocial symptoms or other supportive care needs in adult patients with cancer. A total of 19 publications covering 17 unique studies were included in this review. The RCTs varied in terms of content, duration, and frequency. Nevertheless, we identified 5 elements that were common for the majority of the interventions: an assessment component, tailored symptom self-management support, an information section, a communication section, and a diary. Significant positive effects were observed on QOL in 6 studies, on anxiety in 1 study and depression in 2 studies, on symptom distress in 5 studies, on PA in 4 studies, on dietary behavior in 1 study, and on fatigue in 2 studies. In addition, significant negative effects were observed on anxiety and depression in 1 study. Other studies reported no significant effects on these outcomes (4 studies on QOL, 3 studies on anxiety, 5 studies on depression, 2 studies on symptom distress, 2 studies on PA, 3 studies on dietary behavior, and 3 studies on fatigue). Most interventions were web-based; 2 studies used mobile apps, and 1 study used a game as a DSMST. No relationship was found between the effectiveness of the studies and different components of the DSMSTs for patients with cancer, the quality of the study, and the impact on physical and psychosocial symptoms or other supportive care needs in adult patients with cancer.

Concerning the reported effects of DSMSTs on psychosocial and physical symptoms or other supportive care needs, comparable reviews also showed positive effects of DSMSTs. A systematic review [38] included 16 studies that examined internet-based support programs in patients with cancer. That review showed that internet-based support programs are effective in improving psychosocial and physical symptoms in patients with cancer [38]. Another systematic review included 17 studies that examined web-based mental health interventions in patients with chronic gastrointestinal conditions. That review showed that these interventions resulted in fewer somatic symptoms and improved QOL [39]. Moreover, another review suggested that DSMSTs could be useful for individuals during and after cancer treatment, especially in terms of information, follow-up planning, and management of side effects [14]. However, significant negative effects of DSMSTs were also observed in the reviewed studies. Several studies have reported no significant effects of DSMSTs on specific psychosocial and physical symptoms or other supportive care needs. Other factors may also have played a role in the large variation in observed outcomes. These include the different measurement instruments used within and between studies, different sample sizes, and different periods between the start of the intervention and the postintervention measurement. Future studies should preferably use uniform outcome measures and time intervals for the assessment of outcomes.

For some patients, having more knowledge about their condition might reduce their anxiety as a result of the development of realistic expectations of the future and preparedness for treatment-related side effects. On the contrary, information might also increase patients’ anxiety by drawing attention to their condition, unknown symptoms, or risks of treatment. In our review, one study [21] reported significantly lower anxiety and depression levels in the intervention group than in the control group, whereas another study [34] reported significantly higher anxiety and depression levels in the intervention group than in the control group. In the first study, patients had access to the intervention for 1 year and could use the system as much as they liked. In the second study, patients received a tablet...
Individuals have different preferences regarding information seeking, health care participation, and embracement of DSMSTs. Preferences of women and men might differ regarding health information seeking and support [43]. In addition, age might be of influence, as it might be more difficult to work with new technologies for the older adults [7]. Other factors that could influence the use of new technology are the educational level or the skills needed for using electronic devices [7]. The studies described in this review included patients with different disease or treatment phases. The effects of DSMSTs on physical and psychosocial symptoms or other supportive care needs might differ depending on the patients’ need for information and support, which may vary during the phases. Patients with cancer in the curative phase, for example, may need more information on how to cope with the late effects of surgery or chemotherapy, whereas patients in the palliative phase may want information about the self-management of pain and psychological distress [44]. Future reviews should focus more on comparing the effects of DSMSTs in different groups of patients, distinguished by treatment stage (curative or palliative) and tumor types.

Limitations

Although our review was systematic and we took care to assure its quality, there are limitations to our study. One limitation of this review is that the studies included in the review were conducted predominantly with patients with breast cancer. In addition, several studies included in this review enrolled patients with mixed cancer populations. In some cases, the reported effects and evidence found in the included studies may apply more to one type of patients with cancer than to patients with other tumor types. The preferences and needs of patients with a specific tumor type may differ. Therefore, future studies should focus on specific tumor types. Another limitation is that although the average rating for methodology was good (13 studies were of high quality), the trials included in our review had several potential sources of bias and error. In particular, insufficient information regarding allocation concealment and the lack of blinding participants and personnel as well as outcome assessors might have biased the results. A third limitation is that we summarized different types of self-management support interventions for different types of patient groups and compared their benefits for patient self-management. This heterogeneity hampers firm conclusions regarding the effects on the studied outcomes. In addition, some studies comprised small sample sizes [24,26,32,34]. The absence of significant effects might be caused by a lack of power instead of the true ineffectiveness of the intervention. Due to the large variety of outcome measures, study characteristics, and components of DSMSTs, neither meta-analysis nor a comprehensive description of effect sizes was possible.

Conclusions

In conclusion, this review suggests that DSMSTs have a beneficial effect on the QOL. For effects on other patient outcomes (eg, anxiety and depression, symptom distress, PA, dietary behavior, and fatigue), the evidence is inconsistent and limited or no effect is suggested. A total of 5 elements that were common for the majority of the interventions included an assessment component, tailored symptom self-management support, an information section, a communication section, and a diary. We identified several lacunas in the available body of evidence regarding the effects of DSMSTs on patients with specific tumor types, patients with cancer in a specific treatment stage, and patients in different treatment phases. An earlier review on web-based interventions for type 2 diabetes indicated that interventions of longer duration (>12 weeks) resulted in better outcomes. This may also be the case in patients with cancer [40]. However, further studies are needed to confirm this.

We considered the mode of delivery (how the intervention was delivered to the recipients) in the included studies and identified that the technological component was mainly a web-based approach. Over the past 10 years, the number of publications reporting on the use of DSMSTs in health care has increased. At the beginning of this period, studies focused on telehealth, whereas in the past 5 years, the majority of studies reported on the use of eHealth and mobile health in DSMSTs [7]. Mobile devices have emerged as an important tool for enhancing communication between patients and health care providers, for patient engagement in their health, for disease prevention, and for interventions that change health behavior [13,41]. Surprisingly, we found only 2 studies using mobile health apps, which is in contrast with the rapidly growing market of mobile health apps in general. This may imply that the introduction of new mobile health tools is much faster than its scientific appraisals [7]. To better understand why one device in a care program is more effective than others, adequately conducted studies that moderate the possible effects are needed.

We identified 5 elements that were common for the majority of the interventions: an assessment component, tailored symptom self-management support, an information section, a communication section, and a diary. These elements were used as single-component interventions or multicomponent interventions using different combinations of elements. Of the 16 web-based approach studies, 5 studies used all 5 elements in their DSMSTs [21,25,28,29,32,37] to increase self-management (support). Given the design of the studies, it is difficult to determine whether multicomponent DSMSTs are more effective than single-component DSMSTs and, in the case of a multicomponent DSMST, which particular component contributes most to a certain effect [13]. An earlier review of cancer survivors supported the benefit of an educational element, that is, cancer survivors who received sufficient information reported a better QOL [42]. Most reviews targeting cancer [11-15] highlighted that DSMSTs are mostly multicomponent and that there is a great deal of heterogeneity in the protocols and outcomes measured in cancer - related DSMST studies. Future studies should be more structured to determine the role of individual intervention elements and should take the duration and frequency of interventions into account [13]. To further demonstrate the effects in patients, researchers should analyze and compare single-component and multicomponent DSMSTs separately.

Individuals have different preferences regarding information seeking, health care participation, and embracement of DSMSTs. Preferences of women and men might differ regarding health information seeking and support [43]. In addition, age might...
or disease stage, the design of technology, and especially the design of technology tailored to the patients’ needs. Future research should focus on specific tumor types, study different types of interventions separately, and assess the effects of specific interventions at different stages of disease progression.

**Authors' Contributions**

DJMA was the lead reviewer and drafted the manuscript. MJHMBV was the secondary reviewer for full-text screening, for data extraction, and for quality control. DJMA completed the data analysis and ATMDVD reviewed for accuracy. All authors provided feedback on the draft manuscript. All authors reviewed the final manuscript before submission.

**Conflicts of Interest**

HWMvL has a consultant or advisory role with BMS, Lilly, MSD, Nordic Pharma, Servier, and receives research funding/medication from Bayer, BMS, Celgene, Janssen, Lilly, Merck, Nordic Pharma, Philips, Roche, Servier. The other authors have no conflict to declare.

**References**

1. World Health Organization. Global Status Report on Noncommunicable Diseases 2014. Geneva: World Health Organization; 2014:1-298.
2. Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. J Am Med Assoc 2002 Nov 20;288(19):2469-2475. [doi: 10.1001/jama.288.19.2469] [Medline: 12435261]
3. Van Hecke A, Heinen M, Fernández-Ortega P, Graue M, Hendriks JM, Høy B, et al. Systematic literature review on effectiveness of self-management support interventions in patients with chronic conditions and low socio-economic status. J Adv Nurs 2017 Apr;73(4):775-793. [doi: 10.1111/jan.13159] [Medline: 27653960]
4. Gao WJ, Yuan CR. Self-management programme for cancer patients: a literature review. Int Nurs Rev 2011 Sep;58(3):288-295. [doi: 10.1111/j.1466-7657.2011.00907.x] [Medline: 21848773]
5. Howell D, Harth T, Brown I, Bennett C, Boyko S. Self-management education interventions for patients with cancer: a systematic review. Support Care Cancer 2017 Apr;25(4):1323-1355. [doi: 10.1007/s00520-016-3500-z] [Medline: 28058570]
6. Institute Of Medicine, Board on Health Care Services, Committee on the Crossing the Quality Chasm: Next Steps Toward a New Health Care System. In: Adams K, Greiner AC, Corrigan JM, editors. The 1st Annual Crossing the Quality Chasm Summit: A Focus on Communities: Report of a Summit. Washington, DC: The National Academies Press; 2004:1-176.
7. Kampmeijer R, Pavlova M, Tambor M, Golinowska S, Groot W. The use of e-health and m-health tools in health promotion and primary prevention among older adults: a systematic literature review. BMC Health Serv Res 2016 Sep 05;16 Suppl 5:290 [FREE Full text] [doi: 10.1186/s12913-016-1522-3] [Medline: 27554525]
8. Alpay LL, Henkemans OB, Otten W, Rövekamp TA, Dumay AC. E-health applications and services for patient empowerment: directions for best practices in The Netherlands. Telemed J E Health 2010 Sep;16(7):787-791. [doi: 10.1089/tmj.2009.0156] [Medline: 20815745]
9. Murray E, Burns J, See TS, Lai R, Nazareth I. Interactive health communication applications for people with chronic disease. Cochrane Database Syst Rev 2005(4):CD004274. [doi: 10.1002/14651858.CD004274.pub4] [Medline: 16235356]
10. Kanera IM, Willems RA, Bolman CA, Mesters I, Zambon V, Gijsen BC, et al. Use and appreciation of a tailored self-management eHealth intervention for early cancer survivors: process evaluation of a randomized controlled trial. J Med Internet Res 2016;18(8):e229 [FREE Full text] [doi: 10.2196/jmir.5975] [Medline: 27554525]
11. Goode AD, Lawler SP, Brakenridge CL, Reeves MM, Eakin EG. Telephone, print, and web-based interventions for physical activity, diet, and weight control among cancer survivors: a systematic review. J Cancer Surviv 2015 Mar 11:660-682. [doi: 10.1007/s11764-015-0442-2] [Medline: 25757733]
12. Hong Y, Peña-Purcell NC, Ory MG. Outcomes of online support and resources for cancer survivors: a systematic literature review. Patient Educ Couns 2012 Mar;86(3):288-296. [doi: 10.1016/j.pec.2011.06.014] [Medline: 21798685]
13. Kuipers W, Groen WG, Aaronson NK, van Harten WH. A systematic review of web-based interventions for patient empowerment and physical activity in chronic diseases: relevance for cancer survivors. J Med Internet Res 2013;15(2):e37 [FREE Full text] [doi: 10.2196/jmir.2281] [Medline: 23425685]
14. Odeh B, Kayyali R, Nabhani-Gebara S, Philip N. Optimizing cancer care through mobile health. Support Care Cancer 2015 Jul;23(7):2183-2188. [doi: 10.1007/s00520-015-2627-7] [Medline: 25649121]
15. Seiler A, Klaas V, Tröster G, Fagundes CP. eHealth and mHealth interventions in the treatment of fatigued cancer survivors: a systematic review and meta-analysis. Psychooncology 2017 Sep;26(9):1239-1253. [doi: 10.1002/pon.4489] [Medline: 28665554]
16. Powers MA, Bardsley J, Cypress M, Duker P, Funnell MM, Fischl AH, et al. Diabetes self-management education and support in Type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. J Acad Nutr Diet 2015 Aug;115(8):1323-1334. [doi: 10.1016/j.jand.2015.05.012] [Medline: 26054423]
17. Moher D, Hopewell S, Schulz KF, Montori V, Gatza C, Devereaux PJ. CONSORT. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg 2012;10(1):28-55 [FREE Full text] [doi: 10.1016/j.ijsu.2011.10.001] [Medline: 22036893]

18. Kanera IM, Bolman CA, Willems RA, Mesters I, Lechner L. Lifestyle-related effects of the web-based Kanker Nazorg Wijzer (Cancer Aftercare Guide) intervention for cancer survivors: a randomized controlled trial. J Cancer Surviv 2016 Oct 10;10(5):883-897 [FREE Full text] [doi: 10.1007/s11764-016-0535-6] [Medline: 26984534]

19. Kanera IM, Willems RA, Bolman CA, Mesters I, Verboon P, Lechner L. Long-term effects of a web-based cancer aftercare intervention on moderate physical activity and vegetable consumption among early cancer survivors: a randomized controlled trial. Int J Behav Nutr Phys Act 2017 Feb 10;14(1):19 [FREE Full text] [doi: 10.1186/s12966-017-0474-2] [Medline: 28187725]

20. Willems RA, Mesters I, Lechner L, Kanera IM, Bolman CA. Long-term effectiveness and moderators of a web-based tailored intervention for cancer survivors on social and emotional functioning, depression, and fatigue: randomized controlled trial. J Cancer Surviv 2017 Dec;11(6):691-703 [FREE Full text] [doi: 10.1007/s11764-017-0625-0] [Medline: 28698999]

21. Børsø Sund E, Cvančarova M, Moore SM, Ekstedt M, Ruland CM. Comparing effects in regular practice of e-communication and web-based self-management support among breast cancer patients: preliminary results from a randomized controlled trial. J Med Internet Res 2014;16(12):e295 [FREE Full text] [doi: 10.2196/jmir.3348] [Medline: 25525672]

22. Egbring M, Far E, Roos M, Dietrich M, Brauchbar M, Kullak-Ublick GA, et al. A mobile app to stabilize daily functional activity of breast cancer patients in collaboration with the physician: a randomized controlled clinical trial. J Med Internet Res 2016 Sep 06;18(9):e238 [FREE Full text] [doi: 10.2196/jmir.6414] [Medline: 27601554]

23. Beatty L, Koczvara B, Wade T. Evaluating the efficacy of a self-guided web-based CBT intervention for reducing cancer-distress: a randomized controlled trial. Support Care Cancer 2016 Mar;24(3):1043-1051. [doi: 10.1007/s00520-015-2867-6] [Medline: 26248651]

24. Kim HJ, Kim SM, Shin H, Jang J, Kim YI, Han DH. A mobile game for patients with breast cancer for chemotherapy self-management and quality-of-life improvement: randomized controlled trial. J Med Internet Res 2018 Oct 29;20(10):e273 [FREE Full text] [doi: 10.2196/jmir.9559] [Medline: 30578205]

25. Ruland CM, Andersen T, Jeneson A, Moore S, Grimsbo GH, Børsø Sund E, et al. Effects of an internet support system to assist cancer patients in reducing symptom distress: a randomized controlled trial. Cancer Nurs 2013;36(1):6-17. [doi: 10.1097/CCN.0b013e3182d490d4] [Medline: 22495503]

26. Galiano-Castillo N, Cantarero-Villanueva I, Fernández-Lao C, Ariza-García A, Díaz-Rodríguez L, Del-Moral-Ávila R, et al. Telehealth system: a randomized controlled trial evaluating the impact of an internet-based exercise intervention on quality of life, pain, muscle strength, and fatigue in breast cancer survivors. Cancer 2016 Oct 15;122(20):3166-3174 [FREE Full text] [doi: 10.1002/cncr.30172] [Medline: 27332968]

27. Ryhänen AM, Rankinen S, Siekkinen M, Saarinen M, Korvenranta H, Leino-Kilpi H. The impact of an empowering internet-based breast cancer patient pathway program on breast cancer patients' clinical outcomes: a randomised controlled trial. J Clin Nurs 2013 Apr;22(7-8):1016-1025. [doi: 10.1111/jocn.12007] [Medline: 23480498]

28. Steel JL, Geller DA, Kim KH, Butterfield LH, Spring M, Grady J, et al. Web-based collaborative care intervention to manage cancer-related symptoms in the palliative care setting. Cancer 2016 Apr 15;122(8):1270-1282 [FREE Full text] [doi: 10.1002/cncr.24187725]

29. van den Berg SW, Gielissen MFM, Custers JAE, van der Graaf TA, Ottevanger PB, Prins JB. BREATH: Web-based self-management support among breast cancer patients: preliminary results from a randomized controlled trial. J Cancer Surviv 2015 Sep 1;9(6):790-795. [doi: 10.1007/s11764-015-0535-6] [Medline: 26169621]

30. van der Hout A, van Uden-Kraan CF, Holtmaat K, Jansen F, Lissenberg-Witte BI, Nieuwenhuizen GA, et al. Role of eHealth application Oncokompas in supporting self-management of symptoms and health-related quality of life in cancer survivors: a randomised, controlled trial. J Cancer Surviv 2020 Jan;21(1):80-94. [doi: 10.1016/S1470-2045(19)30675-8] [Medline: 31838009]

31. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010 Jun 1;152(11):726-732. [doi: 10.7326/0003-4819-152-11-201006100-00232] [Medline: 20335313]

32. Lee MK, Yun YH, Park H, Lee ES, Jung KH, Noh D. A web-based self-management exercise and diet intervention for breast cancer survivors: pilot randomized controlled trial. J Int Nurs Stud 2014 Dec;51(12):1557-1567. [doi: 10.1016/j.jinsu.2014.04.012] [Medline: 24856854]

33. Berry DL, Hong F, Halpenny B, Partridge AH, Fann JR, Wolpin S, et al. Electronic self-report assessment for cancer and self-care support: results of a multicenter randomized trial. J Clin Oncol 2014 Jan 20;32(3):199-205 [FREE Full text] [doi: 10.1200/JCO.2013.48.6662] [Medline: 24344222]

34. Foley NM, O’Connell EP, Lehane EA, Livingstone V, Maher B, Kaimkhani S, et al. PATT: Patient accessed tailored information: a pilot study to evaluate the effect on preoperative breast cancer patients of information delivered via a mobile application. Breast 2016 Dec;30:54-58. [doi: 10.1016/j乳房.2016.08.012] [Medline: 27611236]
Urech C, Grossert A, Alder J, Scherer S, Handschin B, Kasenda B, et al. Web-based stress management for newly diagnosed patients with cancer (STREAM): a randomized, wait-list controlled intervention study. J Clin Oncol 2018 Mar 10;36(8):780-788 [FREE Full text] [doi: 10.1200/JCO.2017.74.8491] [Medline: 29369731]

Gustafson DH, DuBenske LL, Namkoong K, Hawkins R, Chih M, Atwood AK, et al. An eHealth system supporting palliative care for patients with non-small cell lung cancer: a randomized trial. Cancer 2013 May 1;119(9):1744-1751 [FREE Full text] [doi: 10.1002/cncr.27939] [Medline: 23355273]

Bantum EO, Albright CL, White KK, Berenberg JL, Layi G, Ritter PL, et al. Surviving and thriving with cancer using a web-based health behavior change intervention: randomized controlled trial. J Med Internet Res 2014;16(2):e54 [FREE Full text] [doi: 10.2196/jmir.3020] [Medline: 24566820]

Bouma G, Admiraal JM, de Vries EG, Schröder CP, Walenkamp AM, Reyners AK. Internet-based support programs to alleviate psychosocial and physical symptoms in cancer patients: a literature analysis. Crit Rev Oncol Hematol 2015 Jul;95(1):26-37. [doi: 10.1016/j.critrevonc.2015.01.011] [Medline: 25701515]

Knowles SR, Mikocka-Walus A. Utilization and efficacy of internet-based eHealth technology in gastroenterology: a systematic review. Scand J Gastroenterol 2014 Apr;49(4):387-408. [doi: 10.3109/00365521.2013.865259] [Medline: 24494974]

Ramadas A, Quek KF, Chan CK, Oldenburg B. Web-based interventions for the management of type 2 diabetes mellitus: a systematic review of recent evidence. Int J Med Inform 2011 Jun;80(6):389-405. [doi: 10.1016/j.ijmedinf.2011.02.002] [Medline: 21481632]

Børresund E, C粪vanaarova M, Ekstedt M, Moore SM, Ruland CM. How user characteristics affect use patterns in web-based illness management support for breast and prostate cancer. J Med Internet Res 2013;15(3):e34 [FREE Full text] [doi: 10.2196/jmir.2285] [Medline: 23454601]

Husson O, Mols F, van de Poll-Franse LV. The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Ann Oncol 2011 Apr;22(4):761-772 [FREE Full text] [doi: 10.1093/annonc/mdq413] [Medline: 20870912]

Ventura F, Ohlén J, Koinberg I. An integrative review of supportive e-health programs in cancer care. Eur J Oncol Nurs 2013 Aug;17(3):498-507. [doi: 10.1016/j.ejon.2012.10.007] [Medline: 23158437]

Slev VN, Mistiaen P, Pasman HR, Verdonck-de Li, van Uden-Kraan CF, Francke AL. Effects of eHealth for patients and informal caregivers confronted with cancer: a meta-review. Int J Med Inform 2016 Mar;87:54-67. [doi: 10.1016/j.ijmedinf.2015.12.013] [Medline: 26806712]

Abbreviations

CONSORT: Consolidated Standards of Reporting Trials
DSMST: digital self-management support tool
HADS: Hospital Anxiety and Depression Scale
PA: physical activity
RCT: randomized controlled trial

©Danielle JM Adriaans, Angelique TM Dierick-van Daele, Marc Johannes Hubertus Maria van Bakel, Grard AP Nieuwenhuijzen, Joep AW Teijink, Fanny FB M Heesakkers, Hanneke WM van Laarhoven. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 29.06.2021. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included.